Jane Street
ELVN icon

Jane Street’s Enliven Therapeutics ELVN Stock Holding History

Jane Street’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.91M Sell
37,600
-5,100
-12% -$217K ﹤0.01% 5241
2026
Q1 		$1.67M Buy
+42,700
New +$1.18M ﹤0.01% 5424

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Jane Street's ELVN Position: Q2 2026 in Review

Jane Street sold out of Enliven Therapeutics (ELVN) in Q2 2026, closing a stake of 163,519 shares — an estimated $6.94M sold.

Jane Street first reported a position in ELVN in Q2 2020 and held it in 11 quarters. The position peaked at $6.41M in Q1 2026. 212 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Jane Street reported no remaining Enliven Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jane Street sold 163,519 Enliven Therapeutics shares in Q2 2026, an estimated $6.94M.
  • Jane Street first reported a position in Enliven Therapeutics in Q2 2020 and held it in 11 quarters.
  • Jane Street's Enliven Therapeutics position peaked at $6.41M in Q1 2026.
  • 212 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.